Larson Tina Marriott's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jan 2, 2024
- Accession no.
- 0001209191-24-000175
- Filed
- Jan 2, 2024
- Trade date
- Dec 28, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $84.6K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Larson Tina MarriottCIK 0001856414 | Officer (President and COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2023 | Class A Common Stock | MOption exerciseAcquired | +8,000 | $1.06 | +$8,480 | 422,548 | Direct | |
| Dec 28, 2023 | Class A Common Stock | SSaleDisposed | −8,000 | $10.58 | −$84,640 | 414,548 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2023 | Class A Common Stock | MOption exerciseDisposed | −8,000 | $0.00 | $0 | 512,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.